Evidence map›Paper›PMID 34796585›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society2022

COVID-19 vaccination timing and kidney transplant waitlist management: An international perspective.

Yasar Caliskan, David Axelrod, Alexis Guenette, Ngan N Lam, Vivek Kute, Tarek Alhamad, Mark A Schnitzler, Krista L Lentine

Open access · bronzeAbstract read
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. COVID-19 vaccination timing and kidney transplant waitlist management: An international perspective.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Yasar CaliskanSaint Louis University Center for Abdominal Transplantation, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0003-3816-8047
David AxelrodUniversity of Iowa/Transplant Institute, Iowa City, Iowa, USA.ORCID https://orcid.org/0000-0001-5684-0613
Alexis GuenetteSaint Louis University Center for Abdominal Transplantation, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-5804-4506
Ngan N LamDivision of Nephrology, Cumming School of Medicine, University of Calgary, Calgary, Canada.ORCID https://orcid.org/0000-0002-0129-7091
Vivek KuteSciences, Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation, Ahmedabad, India.ORCID https://orcid.org/0000-0002-0002-2854
Tarek AlhamadWashington University in St. Louis, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0003-4289-0817
Mark A SchnitzlerSaint Louis University Center for Abdominal Transplantation, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-8547-5643
Krista L LentineSaint Louis University Center for Abdominal Transplantation, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-9423-4849
Saint Louis University · USInstitute of Transplantation Sciences · INUniversity of Calgary · CAUniversity of Iowa · USWashington University in St. Louis · US

Funding

Developing personalized immunosuppression for older kidney transplant recipientsR01DK120518 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MCADAMS DEMARCO, MARA A. · 2019 to 2022
$2.7M
NIDDK NIH HHS R01 DK120518NIH HHS R01DK120518
6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for solid organ transplant programs worldwide. The aim of this study is to assess an international perspective on challenges faced by kidney transplant programs.

methodsWe administered an electronic survey instrument from January 3, 2021 to June 8, 2021 to staff at transplant programs outside the United States that comprised of 10 questions addressing the management of kidney transplant candidates with asymptomatic COVID-19 infection or unvaccinated who receive an organ offer.

resultsRespondents (n = 62) represented 19 countries in five continents. Overall, 90.3% of respondents encourage vaccination on the waiting list and prior to planned living donor transplant. Twelve percent of respondents reported that they have decided to inactivate unsensitized candidates (calculated panel reactive antibody, cPRA <80%) until they received the two doses of vaccination, and 7% report inactivating candidates who have received their first vaccine dose pending receipt of their second dose. The majority (88.5%) of international respondents declined organs for asymptomatic, nucleic acid testing (NAT)+ patients during admission without documented prior infection. However, 22.9% of international respondents proceeded with kidney transplant in NAT+ patients who were at least 30 days from initial diagnosis with negative chest imaging.

conclusionsPractitioners in some countries are less willing to accept deceased donor organs for waitlist candidates with incomplete COVID-19 vaccination status and to wait longer before scheduling living donor transplant, compared to United States practices. Access to vaccinations and other resources may contribute to these differences. More research is needed to guide the optimal approach to vaccination before and after transplant.

Indexed as

COVID-19Kidney TransplantationCOVID-19 VaccinesHumansInternationalitySARS-CoV-2United StatesVaccinationWaiting ListsCOVID-19 VaccinesCOVID-19kidney transplantationoffer acceptancepandemicpracticesvaccinationwaitlist management

Identifiers

PMID34796585
PMCPMC8646503
OpenAlexW3213357985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.